220
Participants
Start Date
August 7, 2024
Primary Completion Date
August 20, 2028
Study Completion Date
February 20, 2035
Linvoseltamab
anti-B-cell maturation antigen x anti-Cluster of differentiation 3 bispecific antibody
RECRUITING
Roswell Park Comprehensive Cancer Center, Buffalo
RECRUITING
Clinica Universidad de Navarra - Pamplona, Pamplona
RECRUITING
Hospital de Cabuenes, Gijón
RECRUITING
SCRI Oncology Partners, Nashville
RECRUITING
Ohio State University, Columbus
RECRUITING
University Hospital La Fe, Valencia
RECRUITING
Karmanos Cancer Institute, Detroit
RECRUITING
MD Anderson Cancer Center, Houston
RECRUITING
Colorado Blood Cancer Institute/SCRI, Denver
RECRUITING
City of Hope, Duarte
RECRUITING
Seoul National University Hospital, Seoul
RECRUITING
Asan Medical Center, Seoul
RECRUITING
Samsung Medical Center, Seoul
RECRUITING
Seoul St. Mary's Hospital - The Catholic University of Korea, Seoul
RECRUITING
Hospital Universitari Son Espases, Palma
RECRUITING
Universität de Barcelona- Institut d' Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona
RECRUITING
University College London Hospitals, London
RECRUITING
The Christie NHS Foundation Trust, Manchester
Regeneron Pharmaceuticals
INDUSTRY